The treatment landscape for major depressive disorder (MDD), consists of numerous safe and effective treatment options, many of which are available as inexpensive generics. Therapies to treat MDD span multiple drug classes, most notably selective serotonin reuptake inhibitors (SSRIs) and serotonin norepinephrine reuptake inhibitors (SNRIs), while other agents, including the newer-to-market Brintellix (Lundbeck’s vortioxetine), offer distinct mechanisms of action; atypical antipsychotics are typically prescribed for patients with a poor response to antidepressants. Ultimately, given the multitude of drugs available to treat depressive symptoms, coupled with the heterogeneous nature of the patient population, treatment is often a trial-and-error process. As such, the treatment algorithm is complex and highly individualized.
Current Treatment: Provides physician insights on prescribing behavior, treatment paths, and the factors and perceptions driving brand usage so you can understand each brand’s performance and improve or defend your competitive position.